Patzak
Adrian Patzak, Regensburg DE
Patent application number | Description | Published |
---|---|---|
20120125367 | SERVICE DEVICE FOR MAINTENANCE OF A SOLAR PANEL ARRANGEMENT - The invention relates to a service device for maintenance of a solar panel arrangement, comprising a service unit for maintenance of at least one surface of the solar panel arrangement, a guiding unit for guiding the service unit with respect to the solar panel arrangement, and a driving unit for moving the service unit with respect to the solar panel arrangement, wherein the service unit comprises a first engagement section and a second engagement section, wherein the guiding unit is attachable to the first engagement section, the guiding unit being configured for direct engagement with an edge of the solar panel arrangement, wherein the driving unit is attachable to the second engagement section, and wherein the second engagement section is displaceable with respect to the first engagement section by the driving unit. | 05-24-2012 |
Adrian Patzak, Munich DE
Patent application number | Description | Published |
---|---|---|
20160087497 | ELECTRICAL MACHINE - The present invention relates to an electrical machine having a stator. The stator comprises a plurality of slots for receiving a stator winding. One respective conductor section of the stator winding is inserted into each slot. The conductor sections of at least one pair of poles are short-circuited to one another on a first side of the stator. The conductor sections on a second side of the stator, opposite from the first side, are each connected to a terminal of a power supply unit. The power supply unit consists of two annular electrical conductors, between which at least one power-electronics component is arranged. | 03-24-2016 |
Conny Patzak, Nuernberg DE
Patent application number | Description | Published |
---|---|---|
20120264614 | LOW TEMPERATURE PRESSURE CHAMBER UNIT, MAGNETIC RESONANCE DEVICE WITH A LOW TEMPERATURE PRESSSURE CHAMBER UNIT, AND AN ATTACHMENT METHOD TO ATTACH AT LEAST ONE ADD-ON UNIT TO AN EXTERNAL HOUSING OF A LOW TEMPERATURE PRESSURE CHAMBER UNIT - In order to attach an add-on unit to a low temperature pressure chamber unit having a low temperature pressure chamber, and an external housing surrounding the low temperature pressure chamber, an attachment device is used to attach at least one add-on unit to the external housing, and the attachment device has an adhesive unit designed for the arrangement and/or attachment of the at least one add-on unit to the external housing. | 10-18-2012 |
Richard Patzak, Aachen DE
Patent application number | Description | Published |
---|---|---|
20080231268 | Imaging Method Based on Fractal Surface-Filling or Space-Filling Curves - The present invention relates to an imaging method and device for nuclear magnetic resonance. On the one hand, the method provides an image coding by means of an additional field which has, for each point of a two-dimensional grating surface within the sample, a different field strength value that occurs only once, as is the case, e.g., in fields based on fractal, surface-filling and space-filling curves. On the other hand, the read-out of the resonance behavior of a sample along a space-filling and/or surface-filling curve can be provided. In the first variant, a magnetic resonance (MR) image with a single high-frequency excitation without a time-varying gradient can be recorded, which in turn advantageously prevents the sound generation associated therewith. In the second variant, the sounds generated during read-out are advantageously shifted to another frequency range in which the human hearing is less sensitive. Furthermore, the device is relieved and the technical requirements with regard to it are reduced. In addition, it can be executed with known and existing devices. | 09-25-2008 |
Ulrich Patzak, Leiderdorp NL
Patent application number | Description | Published |
---|---|---|
20120003309 | Solid Dosage Forms Of Bendamustine - In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable for oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5. | 01-05-2012 |
20140004190 | Solid Dosage Forms of Bendamustine | 01-02-2014 |
20150258070 | Oral Dosage Forms of Bendamustine and Therapeutic Use Thereof - In the present invention there is provided a pharmaceutical composition for oral administration which comprises bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient and which shows a dissolution of the bendamustine of at least 60% in 20 minutes, 70% in 40 minutes and 80% in 60 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of a dissolution medium at a pH of 1.5. The invention further relates to the above pharmaceutical composition for use for the oral treatment of a medical condition which is selected from chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia, acute myelocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer and non-small cell lung cancer. | 09-17-2015 |
20160106716 | Solid Dosage Forms of Bendamustine - In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable or oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5. | 04-21-2016 |
Ulrich Patzak, Ew Leiderdorp NL
Patent application number | Description | Published |
---|---|---|
20130209558 | Oral Dosage Forms of Bendamustine and Therapeutic Use Thereof - In the present invention there is provided a pharmaceutical composition for oral administration which comprises bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient and which shows a dissolution of the bendamustine of at least 60% in 20 minutes, 70% in 40 minutes and 80% in 60 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of a dissolution medium at a pH of 1.5, and wherein the pharmaceutically acceptable excipient is either a pharmaceutically acceptable non-ionic surfactant, selected from the group consisting of a polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide or a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5. The invention further relates to the above pharmaceutical composition for use for the oral treatment of a medical condition which is selected from chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia, acute myelocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer and non-small cell lung cancer. The invention moreover relates to the above pharmaceutical composition for the above use wherein the dosage regimen comprises at least the administration of a dose of 100 to 600 mg/m2/per person of bendamustine on day 1 and day 2, optionally a dose of 50 to 150 mg/m | 08-15-2013 |